Expression of MUC1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients

Fujita, Kazuo; Denda, Kaori; Yamamoto, Masaya; Matsumoto, Takeshi; Fujime, Μakoto; Irimura, Tatsuro

doi:10.1038/sj.bjc.6690355

Cited by 58 publications

(46 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The immunoreactivity for MUC1 in the great majority of renal cell carcinomas in our series is in accordance with the results obtained in other studies, in which immunoreactivity with 'EMA' 27,[45][46][47] or 'MUC1' [3][4][5][6]28 antibodies was observed in 43-100% of renal cell carcinomas. These studies mainly dealt with conventional cancers.…”

Section: Discussionsupporting

confidence: 82%

“…[3][4][5][6]27 These results are based on different criteria for evaluation of immunoreactivity, since some authors restricted themselves to a semiquantitative assessment, 4,27 whereas others also considered staining patterns. 3,5,6 With respect to semiquantitative analysis of MUC1 immunoreactivity, we were unable to reproduce the associations with pT-stage and grade. The stronger immunoreactivity of low-grade papillary carcinomas seems to be caused by stronger staining of the less aggressive type 1 papillary tumors.…”

Section: Discussionmentioning

confidence: 99%

“…26 Regarding renal cell carcinomas, MUC1 expression is common in conventional tumors and has been reported to be associated with tumor grade and stage. [3][4][5][6]27,28 Prognostic relevance, however, is still under debate, since some authors noticed a significant influence on patients' outcome, [3][4][5]27 whereas others failed to detect an influence on tumor aggressiveness in experimental systems. 29 The cadherins constitute a family of transmembrane glycoproteins that function as calcium-dependent homotypic adhesion molecules and are expressed by most epithelia.…”

mentioning

confidence: 99%

“…In the kidney, MUC1 expression was noted on the luminal surfaces of distal tubule and collecting duct epithelium. [3][4][5][6] MUC1 is also known as CD227 or epithelial membrane antigen (EMA). Although EMA is well known in diagnostic histopathology, we prefer the term MUC1 in this study, as it reflects the biological properties and functions of the molecule and furthermore allows its categorization into the growing group of mucin glycoproteins (MUC1-16).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases

et al. 2003

View full text Add to dashboard Cite

MUC1 (epithelial membrane antigen) is a membrane-associated mucin known to interfere with both cell-cell and cell-matrix adhesions. Overexpression has been associated with poor prognosis in a variety of cancers. We investigated the expression of MUC1 (using two different antibodies, MA695 and E29) and E-cadherin in renal cell carcinomas (137 conventional, 23 chromophobe, 20 papillary, and eight unclassified tumors) with respect to diagnostic and prognostic significance using a tissue microarray technique. Immunoreactivity was correlated with histological subtype, pT-stage, and grade using the v 2 test or the Fisher's exact test, respectively. Impact on disease-free survival was analyzed using the Kaplan-Meier method and the log-rank test. Immunoreactivity of more than 10% of cancer cells with MA695, E 29, and E-cadherin antibodies was found in 112/133 (84%), 86/133 (65%), and 7/131 (5%) conventional, 20/22 (91%), 19/22 (86%), and 21/22 (95%) chromophobe, 13/20 (65%), 8/20 (40%), and 3/20 (15%) papillary as well as 5/8 (63%), 5/8 (63%), and 4/8 (50%) unclassified carcinomas, respectively. The two different MUC1 antibodies yielded comparable staining results. A diffuse cytoplasmic staining pattern for MUC1 was found exclusively in chromophobe carcinomas, whereas conventional and papillary subtypes showed predominantly membranous staining (Po0.0001). Regarding papillary carcinomas, MUC1 was predominantly associated with type 1 (P ¼ 0.0001), and E-cadherin with type 2 (P ¼ 0.049) tumors. The cellular staining pattern of MUC1 in conventional tumors was related to pT-stage (P ¼ 0.002) and tumor grade (P ¼ 0.001): Low-stage (pT1/pT2) and grade (G1/G2) tumors showed a predominantly apical membranous staining, high-stage (pT3a/pT3b) and grade (G3/G4) tumors a predominantly circumferential membranous staining (with or without additional diffuse cytoplasmic immunoreactivity), which, in the conventional subtype, was associated with poor prognosis (Po0.0001). In conclusion, MUC1 and E-cadherin are diagnostically and prognostically useful markers in renal tumor pathology, especially when cellular staining patterns are considered. Keywords: kidney; cancer; MUC1; EMA; E-cadherin; differential diagnosis; prognosisMucins are high-molecular-weight (4200 kDa) glycoproteins with oligosaccharides attached to an apomucin protein backbone (core peptide) by Oglycosidic linkage.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases

et al. 2003

View full text Add to dashboard Cite

show abstract

“…From an immunologic standpoint, both an immunostimulatory [8][9][10] and an immunoinhibitory [11,12] role have been proposed. MUC-1 disturbs cell-cell interaction, inhibits aggregation in vitro, and decreases the activity of natural killer cells and lym- www.fhc.viamedica.pl phokine activated killer cells in cancer tissues [13][14][15]. Mucins have been shown to contain complex associations with various cellular pathways, impacting cell growth, proliferation, and apoptosis.…”

Section: Introductionmentioning

confidence: 99%

The levels of sMUC-1 in patients with multiple myeloma

Lemancewicz¹,

Bołkuń²,

Porowska³

et al. 2012

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Abstract:Mucins have been shown to be aberrantly overexpressed in various diseases including cystic fibrosis, asthma, and cancer. Recent studies have uncovered the roles of these mucins in the pathogenesis of cancer. The presence of MUC-1 has also been detected on the cell surface of multiple myeloma (MM) cells in peripheral blood and showed direct correlation with tumor mass. In this study, we evaluated the levels of soluble MUC-1 (sMUC-1) in 50 new MM patients and correlated this with the levels of sMUC-1 after treatment. High levels of sMUC-1 were found in 20/50 (40%) MM patients, and in 2/50 (4%) healthy individuals (p = 0.001). According to the ISS, we found significant differences of mean sMUC-1 levels between the first stage of the disease (0.63 ± ± 0.26) and the third (0.93 ± 0.24; p = 0.03), but not with the second stage (0.80 ± 0.22; p = 0.08). Our study confirmed the correlation between elevated sMUC-1 and high elevated lactate dehydrogenase (p = 0.03) and the level of IgG in groups of patients with MM IgG at every stage of disease (p = 0.001). We showed for the first time that levels of sMUC-1 after treatment, in a group of patients with initially elevated levels of MUC-1, were statistically lower than in a group of patients with initially lower levels of sMUC-1 (21% vs. 42,6%; p = 0.05). At 37 months median of follow-up, we found a statistically significant difference between patients with normal versus elevated sMUC-1 in terms of progression-free survival (median 12 months vs. 8.1 months; p = 0.03).

show abstract

Secondary tumors of the pancreas diagnosed by endoscopic ultrasound‐guided fine‐needle aspiration: A 10‐year experience

Waters

Caraway

et al. 2014

Diagnostic Cytopathology

View full text Add to dashboard Cite

Determining whether a pancreatic mass is a primary or secondary neoplasm is necessary for appropriate treatment. We reviewed our experience using endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for diagnosis of pancreatic tumors to identify clinical and cytopathologic characteristics of metastatic disease. We reviewed all cases of tumors metastatic to the pancreas evaluated at The University of Texas MD Anderson Cancer Center and The Methodist Hospital in Houston, Texas during the period from 2002 to 2012. The review included cytologic specimens, clinical history, radiologic findings, primary tumor type, and clinical follow-up. We identified 66 patients with disease metastatic to the pancreas for which cytologic material was available: 38 (58%) men and 28 (42%) women, with an average age of 63 years (range, 40-89 years). Most metastases (98%) were single lesions, and nearly half were located in the head of the pancreas (30/66). The most common site of origin for these metastases was kidney (27 [41%] cases). Follow-up information was available for 65 (98%) patients, and duration of follow-up ranged from <1 to 10 years (mean, 2.3 years). Thirty-three patients (50%) were alive at the time of the most recent follow-up contact. Of the 25 patients with metastatic renal cell carcinoma, clear cell type, 19 (76%) were alive at the time of the most recent follow-up. It was concluded that metastases may mimic primary pancreatic carcinomas both clinically and cytologically. Ancillary studies in conjunction with clinical history are necessary for the accurate diagnosis of FNAs of secondary pancreatic tumors.

show abstract

Expression of MUC1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients

Cited by 58 publications

References 31 publications

Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases

Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases

The levels of sMUC-1 in patients with multiple myeloma

Secondary tumors of the pancreas diagnosed by endoscopic ultrasound‐guided fine‐needle aspiration: A 10‐year experience

Contact Info

Product

Resources

About